Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozuriftamab vedotin (BA3021) in advanced solid tumors
NCT03504488Phase 2Completed
- Sponsor
- BioAtla
- Start
- Jun 2018
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 2, open-label trial of ozuriftamab vedotin in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 3 more (2 arms), sponsored by BioAtla. Primary endpoints: Safety Profile up to 24 months and Confirmed Objective Response Rate up to 24 months. Started Jun 2018; status: completed.
02
Drugs
ozuriftamab vedotin
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03504488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504488.